Q-omics provides the consensus-scored A4GALT profile across patient tissues and cancer cell-line models. A4GALT expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, A4GALT is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, A4GALT RNA expression shows 17,696 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LIHC, and ACC as cancer lineages where A4GALT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for A4GALT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes A4GALT survival associations across molecular data types. A4GALT RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible A4GALT RNA expression–survival associations across cancer types. High A4GALT expression shows unfavorable associations in UVM and LUAD, but favorable associations in CESC, LUSC, UCEC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for A4GALT RNA expression.
This table summarizes A4GALT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for A4GALT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. A4GALT shows lower tumor expression in KICH and BLCA and higher tumor expression in LIHC, KIRC, HNSC and LUSC. The LIHC box plot shows higher A4GALT RNA expression in tumor versus normal tissue (log2 FC = +1.480, t-test p < 0.001).
This table shows molecular features associated with A4GALT in patient tissues and cancer cell lines. In patient samples, A4GALT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, A4GALT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
